Annexon Inc. (ANNX): Price and Financial Metrics
ANNX Price/Volume Stats
| Current price | $4.78 | 52-week high | $8.40 |
| Prev. close | $4.44 | 52-week low | $1.57 |
| Day low | $4.48 | Volume | 1,050,767 |
| Day high | $4.85 | Avg. volume | 1,489,784 |
| 50-day MA | $5.66 | Dividend yield | N/A |
| 200-day MA | $3.73 | Market Cap | 430.32M |
ANNX Stock Price Chart Interactive Chart >
Annexon Inc. (ANNX) Company Bio
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.
Latest ANNX News From Around the Web
Below are the latest news stories about ANNEXON INC that investors may wish to consider to help them evaluate ANNX as an investment opportunity.
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. PT in San Francisco. A live webcast of the event can be accessed under th |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common StockBRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the pricing of an underwritten public offering of 25,035,000 shares of its common stock and pre-funded warrants to purchase 18,379,861 shares of common stock. The shares of common stock are being sold at a pr |
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary EndpointAlignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians ARCHER II, a Global Sham-Controlled Trial Supporting a Potentially Faster Path to Registration, Expected to Initiate in Mid-2024 ARROW, a Head-to-Head Trial using SYFOVRE® as an Injection Comparator to Differentiate Vision Protection from Slowing of Lesion Growth, Expected to Initiate in Late 2024 BRISBANE, Calif., Dec. 20, 2023 (GLOBE |
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement PathwayTarget Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across Cohorts with No Serious Adverse Events Tablet Formulation of ANX1502 Expected to Advance into Proof-of-Concept Study in Patients with Cold Agglutinin Disease (CAD) in 2024 BRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company dev |
ANNX Price Returns
| 1-mo | -28.01% |
| 3-mo | 3.91% |
| 6-mo | 129.81% |
| 1-year | -12.45% |
| 3-year | -77.32% |
| 5-year | N/A |
| YTD | 5.29% |
| 2023 | -12.19% |
| 2022 | -55.00% |
| 2021 | -54.10% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...